Stevens Capital Management LP Makes New Investment in Pfizer Inc. (NYSE:PFE)

Stevens Capital Management LP purchased a new position in shares of Pfizer Inc. (NYSE:PFE) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 99,037 shares of the biopharmaceutical company’s stock, valued at approximately $2,866,000.

Several other hedge funds also recently bought and sold shares of PFE. MFA Wealth Advisors LLC purchased a new stake in shares of Pfizer in the second quarter valued at $29,000. Gladius Capital Management LP grew its position in shares of Pfizer by 102.8% in the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 38,015 shares during the period. Quarry LP purchased a new stake in shares of Pfizer in the second quarter valued at $31,000. Financial Connections Group Inc. purchased a new stake in shares of Pfizer in the second quarter valued at $34,000. Finally, Teachers Insurance & Annuity Association of America purchased a new stake in shares of Pfizer in the third quarter valued at $35,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Down 1.3 %

Shares of Pfizer stock opened at $25.23 on Thursday. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The firm has a market cap of $142.98 billion, a P/E ratio of 34.10, a P/E/G ratio of 0.69 and a beta of 0.65. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54. The business has a 50-day moving average price of $27.60 and a 200 day moving average price of $28.42.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating the consensus estimate of $0.64 by $0.42. The company had revenue of $17.70 billion during the quarter, compared to analyst estimates of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The business’s revenue was up 31.2% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.17) earnings per share. On average, sell-side analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, December 2nd. Stockholders of record on Friday, November 8th were given a dividend of $0.42 per share. The ex-dividend date of this dividend was Friday, November 8th. This represents a $1.68 annualized dividend and a dividend yield of 6.66%. Pfizer’s dividend payout ratio is presently 227.03%.

Insiders Place Their Bets

In related news, Director Scott Gottlieb acquired 1,000 shares of the business’s stock in a transaction dated Wednesday, October 30th. The stock was bought at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the transaction, the director now owns 10,000 shares of the company’s stock, valued at approximately $282,400. The trade was a 11.11 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.06% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of brokerages recently weighed in on PFE. Sanford C. Bernstein began coverage on Pfizer in a report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 target price on the stock. Citigroup began coverage on Pfizer in a report on Friday, October 25th. They issued a “neutral” rating and a $30.00 target price on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a report on Wednesday, October 23rd. StockNews.com cut Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. Finally, Wolfe Research initiated coverage on Pfizer in a research note on Friday, November 15th. They set an “underperform” rating and a $25.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $32.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.